An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time.

ABSTRACT:

Background

Antibody-mediated protection can depend on mechanisms varying from neutralization to Fc-dependent innate immune-cell recruitment. Adjuvanted vaccine development relies on a holistic understanding of how adjuvants modulate the quantity/titer and quality of the antibody response.

Methods

A Phase 2 trial (ClinicalTrials.gov: NCT00805389) evaluated hepatitis B vaccines formulated with licensed adjuvants (AS01_B, AS01_E, AS03, AS04 or Alum) in antigen-naïve adults. The trial investigated the role of adjuvants in shaping antibody-effector functions, and identified an innate transcriptional response shared by AS01_B, AS01_E and AS03. We integrated previously reported data on the innate response (gene expression, cytokine/C-reactive

SUBMITTER: Tasdighian S 

PROVIDER: S-EPMC11349632 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature